Incidence of major adverse cardiovascular events in patients with rheumatoid arthritis treated with Janus kinase inhibitors compared to biologic disease-modifying antirheumatic drugs : data from an international collaboration of registries (the "JAK-pot" study)

Izpis gradiva
A+ | A- | | SLO | ENG

Naslov:	Incidence of major adverse cardiovascular events in patients with rheumatoid arthritis treated with Janus kinase inhibitors compared to biologic disease-modifying antirheumatic drugs : data from an international collaboration of registries (the "JAK-pot" study)
Avtorji:	ID Aymon, Romain (Avtor) ID Mongin, Denis (Avtor) ID Guemara, Romain (Avtor) ID Salis, Zubeyir (Avtor) ID Askling, Johan (Avtor) ID Choquette, Denis (Avtor) ID Codreanu, Catalin (Avtor) ID Di Giuseppe, Daniela (Avtor) ID Flouri, Irini (Avtor) ID Huschek, Doreen (Avtor) ID Rotar, Žiga (Avtor), et al.
Datoteke:	PDF - Predstavitvena datoteka, prenos (318,67 KB) MD5: C255AE8A2F5D486FA74C04B61E9E023F URL - Izvorni URL, za dostop obiščite https://acrjournals.onlinelibrary.wiley.com/doi/10.1002/art.43188
Jezik:	Angleški jezik
Tipologija:	1.01 - Izvirni znanstveni članek
Organizacija:	UKC LJ - Univerzitetni klinični center Ljubljana
Ključne besede:	adverse cardiovascular events, rheumatoid arthritis, patients, Janus kinase inhibitors, biologic disease-modifying antirheumatic drugs, "JAK-pot" study
Status publikacije:	Objavljeno
Verzija publikacije:	Objavljena publikacija
Leto izida:	2025
Št. strani:	str. 1194-1204
Številčenje:	Vol. 77, no. 9, [article no.] 43188
PID:	20.500.12556/DiRROS-27900
UDK:	616-002
ISSN pri članku:	2326-5191
DOI:	10.1002/art.43188
COBISS.SI-ID:	234984707
Opomba:
Datum objave v DiRROS:	27.02.2026
Število ogledov:	192
Število prenosov:	130
Metapodatki:
:	Kopiraj citat

Objavi na:

Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše podrobnosti ali sproži prenos.

Licenca:	CC BY-NC 4.0, Creative Commons Priznanje avtorstva-Nekomercialno 4.0 Mednarodna

Povezava:	http://creativecommons.org/licenses/by-nc/4.0/deed.sl
Opis:	Licenca Creative Commons, ki prepoveduje komercialno uporabo, vendar uporabniki ne rabijo upravljati materialnih avtorskih pravic na izpeljanih delih z enako licenco.

Jezik:	Slovenski jezik
Naslov:	Objective: To assess the incidence of major adverse cardiovascular events (MACE) in RA patients treated with JAKi, TNF-inhibitors (TNFi) or biologic Disease-Modifying Anti-Rheumatic Drugs with other modes of action (bDMARD-OMA) in a multi-country, real-world population. Methods: RA patients from 15 registries in the JAK-pot collaboration were included. MACE incidence was analysed using two approaches: a within-registry analysis aggregating country-specific estimates from registers with >25 incident MACE events through meta-analysis, and an individual-level data combined analysis. We used adjusted linear mixed Poisson regression to obtain incidence rate ratios (IRR) of MACE between treatment groups, accounting for multiple treatment courses. Results: The study included 73'008 treatment courses (16'417 JAKi, 35'373 TNFi and 21'218 bDMARD-OMA) and 828 incident MACE among 51'233 patients. Median follow-up time was 1.3 years, with most of the follow-up concentrated in the first two years of
Ključne besede:	neželeni srčno-žilni dogodki, revmatoidni artritis, bolniki, zaviralci Janus kinaze, biološkimi antirevmatiki, študija "JAK-pot"

Nazaj